# Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

> **NCT06312670** · PHASE2 · COMPLETED · sponsor: **Pedro Barata, MD, MSc** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** EPI-7386
- **DRUG:** Enzalutamide
- **DRUG:** Androgen Deprivation Therapy (ADT)

## Key facts

- **NCT ID:** NCT06312670
- **Lead sponsor:** Pedro Barata, MD, MSc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-16
- **Primary completion:** 2025-01-09
- **Final completion:** 2025-01-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06312670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06312670, "Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06312670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*